On this page
What belongs in the finished-product control package in CTD P.5?
Present the product specifications, procedures, validation support, batch analyses, relevant impurity characterization and justification as one consistent package. Identify the formulation and purpose of each control. Product-matrix effects, degradation during storage and release versus shelf-life conditions need their own assessment rather than automatic reuse of substance controls.
Before you begin
M4Q(R1) P.5. The tests and criteria depend on dosage form, product performance, impurities and the applicable scientific guidance.
What you will prepare: A product-control package that keeps scope, analytical capability, observed results and proposed limits consistent.
P.5.1–P.5.3: define and measure the proposed quality attributes
In P.5.1, present each proposed product specification with clear scope, tests, methods, units and criteria. Distinguish release and shelf-life specifications where applicable; do not silently use one table for different purposes. Reconcile strengths and dosage forms with P.1.
In P.5.2, describe the analytical procedures for the finished-product matrix. In P.5.3, give the supporting validation information and experimental evidence. Match procedure versions and intended uses. A substance method is not automatically adequate for a formulated product with excipients, degradants or a different sample preparation. Use the applicable current analytical guidance; FDA's Q2(R2) final revision is March 2024.
P.5.4–P.5.5: preserve what the batches and impurity work show
For P.5.4, describe the relevant batches and report the analyses with enough context to identify formulation, manufacturing site/process, scale and intended use. Preserve units and qualifiers. Explain differences that affect comparisons with the proposed product or specification.
For P.5.5, provide impurity characterization not already covered in S.3.2. Examine product-specific formation or change during manufacture and storage using the relevant evidence. Cross-reference existing substance impurity information instead of duplicating it with inconsistent names. Where an impurity's identity, relevance or qualification is unresolved, identify the scientific owner and affected conclusion rather than implying the absence of concern.
P.5.6: explain the control strategy in context
Justify the tests and criteria using development, manufacturing, batch, impurity and stability evidence as appropriate. Explain how the proposed criteria support the product's intended performance and why different release/shelf-life criteria, if proposed, are suitable. A historical internal limit is not its own scientific justification.
Fictional exercise: release data support the proposed impurity criterion, but stability results show a rising degradant. Review P.8's trends and the product impurity assessment with analytical, formulation and safety owners. Determine whether the proposed shelf-life controls and conclusion remain supported. Do not suppress the later data or assume a passing release result establishes acceptability throughout storage.
Separate the purpose of each product control
Use this working grid to make the control proposal reviewable. It does not choose the actual tests or limits.
| Control question | Evidence to inspect | Inconsistency to catch |
|---|---|---|
| What is released? | Formulation, strength and release specification | One table used for materially different products without scope |
| What remains acceptable during storage? | Stability results and relevant shelf-life proposal | Release-only reasoning used for a growing degradant |
| Can the method measure the attribute in this matrix? | Product procedure and validation | Substance validation copied without assessing excipient interference |
| Which batches support the proposal? | Batch identity, process and actual results | Development material presented as the current formulation |
| Why this criterion? | Scientific rationale and supporting assessments | A historical internal limit treated as its own justification |
Review exercise: a degradant is absent at release but increases during storage. The drafting task is to bring the impurity assessment, analytical capability, trend and proposed controls together for technical review. Deleting later values or calling the release criterion a shelf-life limit does not resolve the issue.
Compare the finished-product impurity account with S.3 characterization so shared species retain consistent names while product-specific findings remain visible. Follow the evidence into P.8 stability.
Before release, select one proposed criterion and trace it through all five questions. Missing rationale, incompatible method scope or unrepresentative batches should become specific review issues, not a generic request to make the section more detailed.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Can substance analytical validation automatically support a product assay?
No. The formulated product may introduce matrix effects, different preparation steps or degradation products. Assess the procedure for its intended product use and provide the relevant analytical support. A matching analyte name does not establish suitability in a different matrix.
Must release and shelf-life specifications always be identical?
Do not assume either identity or difference. Where distinct criteria are proposed, define their purposes and provide the scientific justification and relevant stability evidence. The writer should represent the supported control strategy rather than copy one table into both contexts without assessment.
Where should product-specific impurities be explained?
P.5.5 addresses relevant impurity characterization not already covered in the substance account. Cross-reference existing information while preserving product-specific formation or degradation evidence. Reconcile names and conclusions with stability and the proposed controls rather than maintaining conflicting impurity lists.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
ICH M4Q(R1): CTD Quality ↗Step 4, September 12, 2002; Module 3, printed pages 5–18. Organization/content guidance, not a universal list of required studies. Checked September 22, 2026. Guide-specific passages: 3.2.P.5.1–3.2.P.5.6, printed page 15.
Guidance
FDA Q2(R2): Validation of Analytical Procedures ↗Final, March 2024; sections II.A–D (validation study, lifecycle, reportable range, stability indication). PDF and current FDA status page checked; the older Q2A/Q2B citations in M4Q are historical. Checked September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 3.2.P.5. A heading identifies placement, not mandatory applicability.